Jefferies Group Reiterates “Hold” Rating for AstraZeneca plc (AZN)
AstraZeneca plc (LON:AZN)‘s stock had its “hold” rating reaffirmed by stock analysts at Jefferies Group in a report issued on Thursday. They currently have a GBX 4,790 ($81.34) price objective on the stock. Jefferies Group’s price objective indicates a potential upside of 10.41% from the company’s current price.
Shares of AstraZeneca plc (LON:AZN) opened at 4338.50 on Thursday. AstraZeneca plc has a 1-year low of GBX 442.867 and a 1-year high of GBX 5750.00. The stock’s 50-day moving average is GBX 4379.56 and its 200-day moving average is GBX 4172.58. The company’s market cap is £54.752 billion.
Other equities research analysts have also recently issued reports about the stock. Analysts at Swedbank reiterated a “reduce” rating on shares of AstraZeneca plc in a research note on Friday, July 25th. They now have a GBX 3,670.49 ($62.33) price target on the stock. Separately, analysts at Panmure Gordon reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Thursday, July 24th. They now have a GBX 4,400 ($74.72) price target on the stock. Finally, analysts at Deutsche Bank reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Thursday, July 24th. They now have a GBX 3,950 ($67.07) price target on the stock. Seven analysts have rated the stock with a sell rating, seventeen have given a hold rating and six have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of GBX 4,062.63 ($68.99).
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.